Ketamine

Ketamine was first synthesised in 1962 by Calvin Stevens at Parke-Davis as a safer alternative to phencyclidine (PCP) for anaesthetic use. Human trials began in 1964, and by 1970 ketamine had received FDA approval as a dissociative anaesthetic, becoming widely used in emergency medicine, battlefield surgery, and paediatric anaesthesia because it maintains airway reflexes and cardiovascular stability during sedation.

For many years, ketamine’s main psychiatric role was as a pharmacological model of psychosis. Subanesthetic doses were used to study dissociative and perceptual disturbances as a glutamatergic model of schizophrenia, helping to develop the glutamate hypothesis of psychotic disorders alongside the dominant dopamine hypothesis. This work clarified ketamine’s CNS pharmacology in humans and unintentionally set the stage for its later psychiatric applications.

A major turning point occurred in 2000 when Berman et al. at Yale reported that a single subanesthetic IV ketamine infusion (0.5 mg/kg over 40 minutes) produced rapid antidepressant effects in patients with major depression. Zarate et al. at the NIMH replicated and extended these findings in 2006 in treatment-resistant depression, showing robust antidepressant effects emerging within hours and lasting about a week. These studies transformed psychiatric drug development by proving that rapid-acting antidepressant mechanisms were both biologically possible and clinically meaningful.

Over the following decade, clinical research and off-label use expanded rapidly. Ketamine infusion clinics spread across the U.S. and internationally, often operating outside traditional psychiatric regulatory structures and raising concerns about standards of care, patient selection, and commercial motivations. At the same time, drug development efforts concentrated on the S-enantiomer, esketamine, leading to FDA approval of the Spravato nasal spray in 2019. This approval validated glutamatergic antidepressant mechanisms and established a supervised-administration model that has influenced emerging regulatory approaches to psychedelic-assisted therapies.

Ketamine is a non-competitive NMDA receptor antagonist that, at subanesthetic doses (~0.5 mg/kg IV), preferentially blocks NMDA receptors on GABAergic interneurons. This disinhibits glutamatergic neurons, transiently increasing glutamate release and driving downstream AMPA receptor activation, BDNF release, and mTOR signalling, which together are thought to underlie rapid synaptic plasticity and synaptogenesis in prefrontal circuits.

Clinically used ketamine is a racemic mixture of S- (esketamine) and R- (arketamine) enantiomers. Esketamine has ~3–4× higher NMDA receptor affinity and stronger anaesthetic/dissociative effects, whereas preclinical data suggest arketamine may have robust antidepressant effects with fewer side effects, motivating development of both enantiomers as therapeutics.

After IV administration, ketamine reaches peak plasma levels within minutes, with a distribution half-life of ~10–15 minutes and an elimination half-life of ~2–3 hours. It is primarily N-demethylated by CYP3A4 and CYP2B6 to norketamine, then further metabolised to hydroxynorketamine (HNK) and dehydronorketamine (DHNK). The (2R,6R)-HNK metabolite is of particular interest because preclinical work indicates it may exert antidepressant effects via AMPA potentiation without dissociation or abuse liability, though human data remain preliminary.

Ketamine also engages opioid (μ, κ, δ), sigma, monoamine transporter, and cholinergic targets. The contribution of these to antidepressant efficacy is unresolved; a crossover study with naltrexone suggested opioid receptor involvement in acute antidepressant effects, but this interpretation remains debated.

Intranasal esketamine (Spravato) achieves peak plasma concentrations in ~20–40 minutes with ~48% bioavailability. This route allows supervised, non-IV administration but introduces greater pharmacokinetic variability than IV dosing, leading to more variable onset and peak clinical effects across individuals.

Ketamine’s acute side-effect profile at subanesthetic doses is dominated by:

• Dissociative and psychotomimetic symptoms:depersonalisation, derealization, and perceptual distortions.
• Cardiovascular effects:transient increases in blood pressure and heart rate.
• Neurological and systemic symptoms:dizziness, headache, and nausea.

In controlled clinical settings, these effects are usually self-limiting and resolve within 1–2 hours after infusion completion. This time course underlies current requirements for supervised administration and post-dose monitoring of at least two hours.

Serious adverse events during single-dose or short-course IV ketamine protocols in monitored environments are uncommon. Nonetheless, the acute dissociative state can be subjectively distressing, and transient blood pressure elevations may be clinically important in patients with underlying cardiovascular disease. Consequently, most modern protocols exclude individuals with:

• Uncontrolled hypertension
• Unstable cardiovascular disease
• Active psychotic disorders

The safety profile that most clearly differentiates ketamine from classic psychedelics (e.g., psilocybin, LSD) emerges with repeated or chronic exposure. Ketamine has a well-established abuse and dependence liability:

• Produces reinforcing (rewarding) effects
• Tolerance develops with repeated use
• A withdrawal syndrome has been described, including craving, anxiety, and autonomic symptoms

Chronic or heavy recreational ketamine use is associated with a characteristic pattern of end-organ toxicity, including:

• Ketamine-associated ulcerative cystitis:urinary frequency, urgency, haematuria, and in severe cases bladder contracture
• Hepatobiliary dysfunction
• Cognitive impairment:particularly affecting memory and executive function

These chronic-use risks create a different risk-management challenge compared with classic psychedelics. Psilocybin or LSD-assisted therapies typically involve 1–3 supervised sessions, whereas ketamine-based depression treatment often relies on repeated dosing (e.g., twice weekly for several weeks, followed by maintenance infusions) to maintain benefit. The lack of robust long-term safety data for this repeated-dose pattern in psychiatric populations—especially in treatment-resistant depression, where patients may need ongoing treatment for years—is a major unresolved concern.

Drug–drug interactions are relevant but generally manageable in supervised settings:

• Benzodiazepines may attenuate ketamine’s antidepressant response.
• There is theoretical concern about combining ketamine with other pro-glutamatergic or serotonergic agents.
• Lamotrigine has been studied as a pre-treatment to blunt dissociative effects while attempting to preserve antidepressant efficacy, with mixed findings. These data contribute to ongoing debate about whether dissociation is mechanistically linked to ketamine’s therapeutic effects.

The modern evidence base for ketamine and its enantiomers as antidepressants is anchored in a progression from small, mechanistic trials to large, registration-quality programmes.

Berman et al. (2000) first showed in a placebo-controlled crossover RCT that a single IV infusion of racemic ketamine produced rapid antidepressant effects in major depressive disorder. Zarate et al. (2006) at the NIMH replicated and extended these findings in treatment-resistant depression, using the now-standard 0.5 mg/kg IV dose over 40 minutes and a larger sample, thereby establishing the canonical research and clinical protocol.

For S-ketamine (esketamine, Spravato), the pivotal Phase III programme in treatment-resistant depression comprised the TRANSFORM and SUSTAIN trials. The TRANSFORM short-term efficacy studies evaluated intranasal esketamine (56 mg or 84 mg) plus a newly initiated oral antidepressant versus placebo nasal spray plus a newly initiated oral antidepressant. Results were mixed: TRANSFORM-1 failed to meet its primary endpoint, whereas TRANSFORM-2 demonstrated statistically significant superiority of esketamine on the MADRS, providing key acute-efficacy evidence. SUSTAIN-1, a maintenance trial, showed that continued esketamine treatment reduced relapse risk compared with discontinuation, supporting its role in long-term management and contributing critically to regulatory approval.

A separate Phase III programme targeted major depressive disorder with acute suicidal ideation or behaviour. The ASPIRE I and ASPIRE II trials tested intranasal esketamine plus standard of care against placebo plus standard of care. Both demonstrated rapid reductions in depressive symptoms at 24 hours, leading to a supplemental FDA approval in 2020 for use in MDD with acute suicidal ideation or behaviour. These studies were notable for enrolling a population with imminent safety concerns and for demonstrating clinically meaningful effects in the context of acute suicidal risk, even though effects on suicidal ideation per se were more nuanced.

Racemic IV ketamine has also been explored in numerous investigator-initiated trials across indications beyond treatment-resistant unipolar depression. In bipolar depression, Diazgranados et al. reported rapid antidepressant effects comparable to those seen in unipolar TRD, suggesting transdiagnostic efficacy across mood disorders. In PTSD, multiple small RCTs and controlled studies have yielded mixed but generally encouraging results, with several groups reporting reductions in core PTSD symptoms that justify larger, more definitive trials. Additional exploratory work has examined ketamine in obsessive-compulsive disorder, chronic pain syndromes, and various substance use disorders, where preliminary signals suggest potential therapeutic benefit but remain less well established than in depression.

The arketamine (R-ketamine) development programme is earlier but conceptually important. Preclinical work by Hashimoto and colleagues has indicated robust, sustained antidepressant-like effects of arketamine in animal models, with a potentially more favourable side-effect profile and reduced dissociation compared with S-ketamine. These findings have prompted early-phase human studies assessing safety, tolerability, pharmacokinetics, and preliminary antidepressant efficacy in depression. While definitive clinical data are still emerging, arketamine represents a promising next-generation candidate that may help disentangle the mechanistic contributions of different ketamine enantiomers to rapid antidepressant action.

Ketamine-based therapeutics are consolidating around several key axes of development and clinical uncertainty:

1. Treatment-resistant depression (TRD) as the anchor indication

Esketamine (Spravato) has established ketamine’s role in TRD and is generating real-world evidence on utilisation, durability of response, and safety. However, major unanswered questions remain:

• Optimal treatment duration: How long patients should remain on esketamine or ketamine after achieving response or remission is not yet defined.
• Maintenance dosing frequency: The ideal interval and tapering strategy for maintenance dosing to balance efficacy, convenience, and safety is unclear.
• Long-term safety: It is unknown whether chronic, repeated exposure leads to cumulative cognitive, urological (e.g., ketamine cystitis–like syndromes), or hepatic toxicity beyond what is captured in relatively short and selective clinical trials.

1. Acute suicidality as a frontier indication

Ketamine’s rapid onset offers a potentially unique advantage in acute suicidal crises, where current pharmacological options are inadequate for immediate relief. Key issues include:

• Demonstrating that rapid symptom reduction (suicidal ideation, agitation, despair) leads to sustained reductions in suicidal behaviour (attempts, hospitalisations, deaths), rather than transient mood improvement alone.
• Integrating ketamine-based interventions into emergency and crisis-care pathways, including logistics, monitoring, and post-discharge continuation strategies.

1. Arketamine (R-ketamine) as a potential paradigm shift

Arketamine development aims to decouple antidepressant efficacy from dissociation and abuse liability. If ongoing trials confirm preclinical signals:

• It could provide robust antidepressant effects with fewer dissociative and psychotomimetic side effects.
• Lower abuse potential and reduced need for intensive monitoring could expand the eligible patient population and enable broader outpatient or primary-care use.

1. Next-generation NMDA modulators and glutamatergic antidepressants

Ketamine has catalysed a broader search for rapid-acting antidepressants targeting glutamatergic pathways, including:

• GluN2B-selective NMDA antagonists
• AMPA receptor potentiators
• mGluR (metabotropic glutamate receptor) modulators

These programmes aim to reproduce ketamine’s rapid antidepressant effects while avoiding dissociation, psychotomimetic reactions, and abuse liability. Their success or failure will determine whether:

• Ketamine remains a unique, niche rapid-acting agent, or
• Becomes the prototype of a broader class of glutamatergic rapid-acting antidepressants.

1. Chronic pain and anaesthesia: evolving but established roles

Beyond psychiatry, ketamine continues to evolve in:

• Chronic and refractory pain: Low-dose infusions are used (often off-label) for complex regional pain syndrome, neuropathic pain, and opioid-resistant cancer pain, with ongoing work to define optimal dosing, duration, and patient selection.
• Perioperative care and anaesthesia: Ketamine is increasingly integrated into multimodal analgesia and opioid-sparing protocols within enhanced recovery after surgery (ERAS) pathways, aiming to reduce opioid exposure while maintaining effective pain control.

Collectively, these trajectories will determine whether ketamine remains primarily a specialised intervention for TRD and select pain/anaesthesia settings, or becomes the foundation for a broader, safer, and more scalable class of rapid-acting neuropsychiatric therapeutics.

Ketamine's regulatory picture is split across two different lanes. Esketamine nasal spray has an FDA-labeled pathway for depression indications, including treatment-resistant depression, while racemic ketamine remains widely discussed through off-label infusion and compounded-product practice rather than a single FDA-approved depression product. [1]FDA Spravato label

That distinction matters because evidence, monitoring, reimbursement, and safety obligations differ by product and route. The FDA has separately warned about risks associated with compounded ketamine products, so commercial availability should not stand in for regulated clinical approval. [2]FDA compounded ketamine warning

The evidence base is clearest when regulatory and safety claims stay product-specific: esketamine label, off-label racemic ketamine, and compounded formulations are related but not interchangeable.

Ketamine currently represents the most commercially advanced asset in the psychedelic-adjacent therapeutics space, supported by both an approved branded product and a large, fragmented off-label market.

Spravato (esketamine, Janssen/J&J) is the flagship approved product, generating approximately $906 million in global sales in 2023, placing it among the top-revenue novel antidepressants. Its performance validates payer willingness to reimburse for rapid-acting antidepressant mechanisms under structured REMS-like frameworks, but also highlights the importance of strong commercial infrastructure and market access capabilities.

In parallel, a substantial off-label IV ketamine ecosystem has developed. An estimated 500–800 ketamine clinics operate in the U.S., typically offering racemic ketamine infusions for treatment-resistant depression, anxiety disorders, PTSD, and chronic pain. While some players (e.g., Nue Life Health, Field Trip Health/Reunion Neuroscience) have attempted to build scaled, multi-site clinic networks, the economics are challenging: generic ketamine is inexpensive, protocols are largely cash-pay due to limited insurance coverage, and fixed costs for clinical staffing and real estate compress margins.

Next-generation NMDA receptor modulators aim to capture ketamine-like efficacy with improved tolerability, safety, and convenience. Key programs include:

• Arketamine (R-ketamine) from Perception Neuroscience/Atai Life Sciences, positioned as a potentially more tolerable, longer-acting enantiomer with rapid antidepressant effects.
• PCN-101, an intranasal arketamine formulation, targeting more convenient administration versus IV infusions.
• Rapastinel and apimostinel (Allergan/AbbVie), which sought to leverage NMDA modulation without classic ketamine dissociation, though clinical setbacks have limited their near-term prospects.
• REL-1017 (esmethadone) from Relmada Therapeutics, a novel NMDA receptor modulator being evaluated as an oral antidepressant with a differentiated safety and side-effect profile.

Telehealth-enabled, at-home ketamine treatment emerged as a major growth vector during the COVID-19 pandemic, primarily via sublingual and intranasal compounded formulations. Consumer-facing platforms such as Mindbloom and Joyous scaled rapidly by combining remote psychiatric evaluation, digital monitoring, and at-home dosing. However, this model now faces increasing regulatory friction: the FDA has raised concerns about compounded ketamine products, and an FDA advisory committee has scrutinized unsupervised or lightly supervised at-home use, creating uncertainty around the long-term viability and reimbursement outlook of this segment.

Overall, ketamine’s landscape spans: (1) a high-revenue, branded, on-label product (Spravato); (2) a large but economically constrained off-label clinic market; (3) a pipeline of next-generation NMDA modulators seeking better risk–benefit and delivery profiles; and (4) a telehealth/at-home segment under growing regulatory pressure. This combination makes ketamine the most commercially mature and diversified asset class within the broader psychedelic-adjacent therapeutics domain.

Ketamine occupies a unique niche among psychedelic-adjacent therapies. It is currently the only agent in this space with an approved psychiatric indication (treatment-resistant depression for esketamine/Spravato), the largest real-world and clinical evidence base, and the most developed commercial delivery infrastructure. Yet its biology, subjective effects, and care model diverge meaningfully from classic serotonergic psychedelics and MDMA.

Mechanism and Subjective Effects

Classic psychedelics such as psilocybin, LSD, DMT, and mescaline exert their primary effects via agonism at the serotonin 5-HT2A receptor, leading to characteristic alterations in perception, cognition, and emotion. In contrast, ketamine is an NMDA receptor antagonist that modulates glutamatergic signalling and downstream synaptic plasticity pathways (e.g., via AMPA activation, BDNF, and mTOR). As a result, its antidepressant mechanism is pharmacologically distinct from that of serotonergic psychedelics.

Phenomenologically, ketamine tends to produce dissociation, depersonalisation, and alterations in body perception rather than the vivid sensory, emotional, and meaning-laden experiences typical of classic psychedelics. Whether ketamine’s subjective experience is necessary or incidental to its antidepressant effect remains unresolved, whereas for classic psychedelics the intensity and quality of the so‑called “mystical” or peak experience are increasingly viewed as mediators of therapeutic outcome.

Efficacy, Onset, and Durability

Ketamine’s most notable clinical advantage is speed of onset. Antidepressant effects can emerge within hours, making it one of the fastest-acting interventions for severe or treatment-resistant depression and acute suicidality. However, these benefits are usually transient: without maintenance dosing, clinical effects often diminish within days to roughly two weeks.

By comparison, psilocybin-assisted therapy trials have demonstrated sustained antidepressant responses lasting weeks to months after only one or two high-dose sessions embedded in a structured therapeutic framework. MDMA-assisted therapy for PTSD has shown durable symptom reduction persisting at least 12 months post-treatment in controlled studies. This contrast highlights ketamine’s relative lack of durability and positions it closer to conventional antidepressants that require ongoing administration, rather than to the “catalytic” or episodic treatment model envisioned for psychedelic-assisted therapies.

Therapeutic Model and Psychotherapy Integration

Standard ketamine treatment protocols typically involve limited preparatory work, a monitored infusion or intranasal administration, and minimal formal integration afterwards. The emphasis is often on pharmacologic action rather than on intensive psychotherapeutic processing of the experience.

In contrast, psilocybin- and MDMA-assisted therapies are built around a high-touch model: multiple preparatory sessions, extended dosing sessions with trained therapists, and structured integration over subsequent weeks. Some clinicians and researchers are developing ketamine-assisted psychotherapy (KAP) approaches that pair sub-anaesthetic ketamine dosing with targeted psychotherapy, aiming to leverage ketamine’s neuroplastic and experiential effects. However, these models are heterogeneous, not standardised, and are not embedded in the approved Spravato protocol. The lower psychotherapy burden of typical ketamine care reduces cost and training demands but may also constrain the depth and durability of psychological change.

Safety, Regulation, and Access

Ketamine benefits from decades of use as an anaesthetic, yielding a well-characterised safety profile and facilitating its adoption in psychiatry under existing regulatory frameworks. Clinicians can prescribe ketamine off-label or administer esketamine within REMS programs today, without awaiting new approvals for classic psychedelics or MDMA.

At the same time, ketamine carries recognised risks: abuse and dependence potential, cognitive and urinary tract complications with heavy or prolonged use, and variable quality of care across rapidly proliferating clinics. These concerns are amplified by patterns of chronic or high-frequency dosing that diverge from the short-course, tightly controlled protocols used in psychedelic trials. Investigational psychedelics, while less accessible, are currently administered under rigorous trial conditions that limit misuse and standardise support.

Overall, ketamine stands as a pragmatic, immediately available intervention with rapid antidepressant effects and a comparatively well-understood risk profile, but with limitations in durability and depth of psychological transformation. Classic psychedelics and MDMA, though earlier in their regulatory journeys, are being developed within more intensive psychotherapeutic frameworks that may yield longer-lasting change at the cost of greater complexity and resource requirements.